When can eliquis become generic?

When does Eliquis (apixaban) lose exclusivity?

Eliquis (apixaban) becomes eligible for generic entry after key patent and exclusivity barriers expire. Generic timing depends on the specific patents covering Eliquis and whether the U.S. Food and Drug Administration (FDA) grants any additional exclusivity (for example, pediatric exclusivity can extend regulatory exclusivity for some drugs). Patent challenges and court rulings can also change the timeline.

What matters for “generic Eliquis” in the U.S.?

For brand-to-generic switches, the practical dates are usually driven by:
- Patent expiration dates for apixaban in its approved form and method-of-use
- Any regulatory exclusivity periods attached to the brand product
- The status of FDA “paragraph IV” challenges (if a generic applicant has sued to invalidate patents)
- Court decisions that can delay or allow market entry

If you want, I can translate those steps into a specific expected earliest generic-available window—but I would need the exact jurisdiction/date reference you care about (U.S. vs. another country).

Where can I check the latest Eliquis patent/generic-entry dates?

DrugPatentWatch.com tracks Eliquis apixaban patent information and generic-entry expectations and is a useful place to verify the most current status: https://www.drugpatentwatch.com/ (search “Eliquis” or “apixaban” there).

Can generics launch right after patent expiry?

Even after a relevant patent expires, generics may still require:
- FDA approval for generic labeling/bioequivalence
- Any remaining exclusivity (if applicable)
- Resolution of any ongoing litigation that affects market entry

Do biosimilars affect Eliquis’s generic timeline?

No. Eliquis is a small-molecule drug (apixaban), so it follows generic small-molecule pathways rather than biosimilar pathways.

Sources

1. DrugPatentWatch.com